Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
AUSTIN, Texas, May 03, 2018 -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its first quarter ended March 31, 2018 financial results on Monday, May 14, 2018, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.
| Monday, May 14th @ 4:30pm Eastern Time | |||
| Domestic: | 800-239-9838 | ||
| International: | 323-794-2551 | ||
| Conference ID: | 5200441 | ||
| Webcast: | http://public.viavid.com/index.php?id=129615 | ||
| Replays, Available through May 28: | |||
| Domestic: | 844-512-2921 | ||
| International: | 412-317-6671 | ||
| Replay PIN: | 5200441 | ||
About Vermillion
Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company's initial in vitro diagnostic test, OVA1® (MIA), was the first FDA cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. Vermillion, Inc.’s tests are intended to characterize and stage disease, and to help guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in monitoring response to therapy.
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel 617-535-7742
[email protected]
